Future Science OA is an esteemed open-access journal published by FUTURE SCI LTD, dedicated to advancing knowledge in the fields of biotechnology and medicine. Established in 2015, this journal has rapidly gained recognition within the scientific community, evidenced by its impressive ranking in both General Medicine (Rank #100/636, 84th percentile) and Biotechnology (Rank #145/311, 53rd percentile) as per Scopus metrics. With a Q2 category quartile in both fields as of 2023, Future Science OA provides a vital platform for researchers, professionals, and students to share groundbreaking research and innovative ideas. Notably, being an open-access journal allows for a wider dissemination of knowledge, ensuring equal access to high-quality research for practitioners and scholars alike. Based in the United Kingdom, Future Science OA is committed to fostering collaboration and dialogue within the scientific community, making it a cornerstone resource for advancing the future of the life sciences.

EPIDEMIOLOGIE MIKROBIOLOGIE IMUNOLOGIE is a prominent scholarly journal published by CESKA LEKARSKA SPOLECNOST J EV PURKYNE in the Czech Republic. With an ISSN of 1210-7913, this journal has been at the forefront of research since its inception in 1994, showcasing a rich repository of studies bridging the domains of epidemiology, microbiology, immunology, and infectious diseases, and reflecting advancements over three decades. Although it currently falls within the Q4 category in multiple fields including Epidemiology and Microbiology, the journal serves an essential role in disseminating knowledge and fostering discussions around public health challenges. The contributions made through its pages are vital for researchers, healthcare professionals, and students aiming to enhance their understanding of complex biomedical issues. While it does not offer open access, the journal remains a critical resource in its niches, inviting readers to engage with the latest findings and methodologies reshaping the landscape of health science.

Open Forum Infectious Diseases (ISSN: 2328-8957; E-ISSN: 2328-8957) is a leading open-access journal published by Oxford University Press, dedicated to advancing the field of infectious diseases. Since its inception in 2014, the journal has provided a platform for researchers to disseminate impactful findings in a rapidly evolving domain, achieving a remarkable Q1 ranking in both the Infectious Diseases and Oncology categories as of 2023. The journal encourages rigorous and innovative research, contributing significantly to global health discussions and informing best practices in clinical settings. As an open-access journal, it ensures that its content is accessible to a wide audience, fostering collaboration and knowledge sharing among researchers, professionals, and students alike. Positioned in the heart of the United States, Open Forum Infectious Diseases serves as a critical resource for the academic community, and its continued commitment to quality and relevance secures its status as an essential publication in the field.

Emerging Microbes & Infections is a premier open access journal, published by Taylor & Francis Ltd since 2012, dedicated to advancing the understanding of microbial infections and their implications in human health. With an impressive Q1 ranking across multiple categories—including Drug Discovery, Epidemiology, Immunology, and Infectious Diseases—this journal is at the forefront of research in the microbiological sciences. Covering a diverse range of topics, it serves as a vital resource for researchers, healthcare professionals, and students alike. The journal's commitment to open access ensures worldwide dissemination of cutting-edge findings, fostering collaboration and innovation in tackling challenges posed by emerging infections. As part of the thriving academic community in the United Kingdom, Emerging Microbes & Infections plays a crucial role in shaping the future of infectious disease research and public health.

Infectious Agents and Cancer is a pivotal open access journal published by BMC, dedicated to advancing research at the intersection of infectious diseases and oncology. Since its inception in 2006, this journal has provided a platform for the exploration of the complex relationships between infectious agents and cancer development, aimed at researchers, healthcare professionals, and students alike. With a broad scope encompassing epidemiology and cancer research, the journal holds an impressive ranking in the Q3 quadrant for epidemiology, infectious diseases, and oncology in 2023, while also featuring in the Q4 category for cancer research. This distinguished journal not only contributes to the enrichment of scientific knowledge but also fosters collaborative efforts towards innovative solutions in the fight against cancer. Being part of the UK publishing landscape, the journal is accessible to a global audience, ensuring that vital research findings are disseminated widely to inform policy and practice in health sciences.

Influenza and Other Respiratory Viruses, published by WILEY, serves as a prominent peer-reviewed platform for the dissemination of research contributing to the understanding and management of respiratory viral infections. With an impressive impact factor and established as an Open Access journal since 2014, it ensures maximum visibility and accessibility of pivotal research findings in the realm of Epidemiology, Infectious Diseases, Public Health, and Pulmonary and Respiratory Medicine. Registered under the ISSN 1750-2640 and E-ISSN 1750-2659, the journal boasts Q1 rankings in four critical categories as of 2023, underscoring its significance within the scientific community. Researchers, professionals, and students can benefit from the convergence of knowledge that this journal facilitates from 2007 to 2024, fostering advancements in understanding viral pathogens and innovative treatment strategies that are increasingly vital to public health efforts globally.

Human Vaccines & Immunotherapeutics, published by TAYLOR & FRANCIS INC, stands at the forefront of immunology and vaccine research, presenting critical advancements and innovative approaches to immunotherapy since its inception in 2012. With an impressive impact factor and rankings in the top quartiles of leading categories such as Immunology, Pharmacology, and Medicine, this journal serves as a vital resource for researchers, healthcare professionals, and students who are dedicated to advancing the understanding and application of vaccines and immunotherapeutic strategies. Offering Open Access options for enhanced visibility and outreach, the journal encourages the dissemination of high-quality research that can drive meaningful impact in public health. Its continuous commitment to excellence is reflected in its ranking metrics—ranking #71 in Pharmacology with a 77th percentile and #69 in Immunology and Allergy with a 70th percentile, ensuring that it remains a preferred forum for notable scholarly contributions in a rapidly evolving field.

npj Vaccines, published by NATURE PORTFOLIO, is an esteemed Open Access journal that has been at the forefront of vaccination research since its inception in 2016. With an impressive impact factor and ranking in the top quartile (Q1) across several categories including Immunology, Infectious Diseases, and Pharmacology, this journal provides a crucial platform for the dissemination of high-quality research and innovative findings in the field of vaccine development. Based in the United Kingdom, and with its broad scope encompassing both fundamental and translational studies, npj Vaccines facilitates significant discourse among researchers, professionals, and students dedicated to immunization strategies and public health. The journal's commitment to Open Access ensures that vital knowledge is shared widely, promoting collaboration and advancement in vaccine science on a global scale. Scholars are encouraged to contribute to this essential field, as their findings may significantly impact the future of disease prevention and control.

Journal of Pediatric Infection is a vital academic resource dedicated to the ever-evolving field of infectious diseases in pediatric populations. Published by AVES YAYINCILIK in Turkey, this journal features a rigorous peer-review process and has established itself as a platform for innovative research from around the globe. Although currently categorized in the Q4 quartile for both Infectious Diseases and Pediatrics, Perinatology and Child Health, the journal's potential for growth is substantial, attracting contributions that aim to shed light on the complexities of infectious diseases affecting children. With a converged publication history from 2009 to 2024, the journal emphasizes the importance of advancing knowledge in pediatric health through systematic reviews, original research, and case studies. Its open access policy encourages unrestricted sharing of vital research findings, making it an essential read for researchers, clinicians, and students dedicated to improving pediatric healthcare outcomes.

The Japanese Journal of Infectious Diseases, published by the National Institute of Infectious Diseases in Japan, serves as a vital platform for researchers, clinicians, and public health professionals committed to advancing the field of infectious disease science. With an ISSN of 1344-6304 and an E-ISSN of 1884-2836, this journal has maintained its academic rigor since its inception in 1961 and continues to contribute significantly to the global understanding of infectious diseases. The journal holds a Q3 ranking in the categories of Infectious Diseases, Miscellaneous Medicine, and Medical Microbiology as of 2023, reflecting its important role in disseminating impactful research. With many articles available through Open Access, it ensures wide accessibility to the latest discoveries and insights. Researchers can expect to find high-quality studies that address critical challenges in the control and prevention of infectious diseases, making this journal an essential resource for anyone engaging in this critical field.